Manufacturing
Theragent to act as partner for CellVax’s Phase II cancer therapy
CellVax will examine and evaluate how FK-PC101 reduces the recurrence of prostate-specific antigens in patients.
Myelofibrosis market to see new approvals in 2022, driving market growth
UNION’s orismilast enters Phase IIb and a crowded small molecule market
Is precision medicine the future of obesity treatment?
National Thyroid Awareness Month shines a spotlight on disorders like hypothyroidism
Global warning: pharma’s role in the climate crisis
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
